HTD Stock Chart & Stats
€82.86
-€2.48(-2.91%)
At close: 4:00 PM EDT
€82.86
-€2.48(-2.91%)
Day’s Range― - ―
52-Week Range€27.49 - €85.82
Previous CloseN/A
Volume115.00
Average Volume (3M)25.00
Market Cap
€9.00B
Enterprise Value€3.88K
Total Cash (Recent Filing)€338.18M
Total Debt (Recent Filing)€9.64M
Price to Earnings (P/E)211.9
Beta-0.22
Next Earnings
Jul 29, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.45
Shares Outstanding107,351,590
10 Day Avg. Volume32
30 Day Avg. Volume25
Financial Highlights & Ratios
PEG Ratio-1.24
Price to Book (P/B)5.58
Price to Sales (P/S)4.75
P/FCF Ratio25.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€77.36Price Target Upside-6.64% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)0.51
Revenue Forecast (FY)€878.85M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low debt-to-equity and sizable equity ($638M–$680M) give Corcept durable financial flexibility. This cushion supports multi-year commercial launches, pipeline spend, and potential M&A without forcing dilutive financing, reducing solvency risk during expansion or temporary revenue lags.
Strong Cash Runway And Cash GenerationA $515M cash balance combined with historically healthy operating cash flow provides lasting runway to fund Lifyorli launch investments, specialty pharmacy network expansion and late‑stage trials. Robust liquidity lowers near‑term refinancing risk and preserves optionality across development priorities.
High-impact Clinical/regulatory Win (Lifyorli/ROSELLA)A statistically significant survival benefit and rapid FDA approval create durable commercial and guideline momentum. NCCN inclusion and early prescriber uptake underpin structural revenue diversification beyond endocrine indications, supporting multi-year upside if adoption and payer coverage scale as projected.
Bears Say
Profitability Deterioration / Q1 Net LossOperating expenses rose sharply for launch and growth investments, driving a swing to loss despite revenue growth; net margin has compressed materially versus prior years. If margin pressure persists, it could reduce free‑cash‑flow conversion and limit reinvestment without using cash reserves or raising capital.
Concentration On Endocrine Revenue While Oncology Is EarlyAlthough Lifyorli shows early traction, oncology revenues are not yet a primary driver. Continued reliance on the endocrine franchise makes near‑term growth sensitive to screening, reauthorizations and payer dynamics; slower oncology scale or reimbursement delays would keep revenue concentration risk intact.
Prolonged Legal Uncertainty (amended Qui Tam)An amended qui tam suit that proceeds without DOJ intervention can extend litigation timelines and unpredictability. Even absent immediate government action, protracted legal exposure elevates potential settlement or defense costs, regulatory distraction, and reputational risk with payers and providers over the medium term.
Corcept Therapeutics News
HTD FAQ
What was Corcept Therapeutics’s price range in the past 12 months?
Corcept Therapeutics lowest stock price was €27.49 and its highest was €85.82 in the past 12 months.
What is Corcept Therapeutics’s market cap?
Corcept Therapeutics’s market cap is €9.00B.
When is Corcept Therapeutics’s upcoming earnings report date?
Corcept Therapeutics’s upcoming earnings report date is Jul 29, 2026 which is today.
How were Corcept Therapeutics’s earnings last quarter?
Corcept Therapeutics released its earnings results on Apr 30, 2026. The company reported -€0.264 earnings per share for the quarter, missing the consensus estimate of -€0.097 by -€0.167.
Is Corcept Therapeutics overvalued?
According to Wall Street analysts Corcept Therapeutics’s price is currently Overvalued.
Does Corcept Therapeutics pay dividends?
Corcept Therapeutics does not currently pay dividends.
What is Corcept Therapeutics’s EPS estimate?
Corcept Therapeutics’s EPS estimate is 0.02.
How many shares outstanding does Corcept Therapeutics have?
Corcept Therapeutics has 107,351,590 shares outstanding.
What happened to Corcept Therapeutics’s price movement after its last earnings report?
Corcept Therapeutics reported an EPS of -€0.264 in its last earnings report, missing expectations of -€0.097. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Corcept Therapeutics?
Currently, no hedge funds are holding shares in DE:HTD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Corcept Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€77.36 (-6.64% Downside)
€77.36 (-6.64% Downside)
Blogger Sentiment
Bullish
DE:HTD Sentiment 67%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $2.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Bullish
Bullish news 75%
Bearish news 25%
Bearish news 25%
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.08%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-3.73%
Trailing 12-Months
Company Description
Corcept Therapeutics
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
HTD Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong positive momentum driven by major clinical and regulatory milestones (Lifyorli FDA approval with a significant survival benefit, landmark CATALYST and MOMENTUM findings that broaden the addressable market, robust patient and prescriber growth, raised 2026 guidance, and compelling ALS and MASH data). Near-term negatives include a Q1 earnings swing to a net loss, temporary revenue headwinds from insurance reauthorizations and a pharmacy-transition backlog, and tolerability-related discontinuations in DAZALS that require mitigation. On balance, the company demonstrated durable commercial traction, an expanding pipeline with high-impact results, and clear plans to address operational issues, leading to a favorable outlook.View all DE:HTD earnings summariesHTD Stock 12 Month Forecast
Average Price Target
€77.36
▼(-6.64% Downside)
Technical Analysis
Jazz Pharmaceuticals
―
Axsome Therapeutics
―
Rhythm Pharmaceuticals
―
Revolution Medicines
―
Legend Biotech
―